Opko Health, Inc. · NASDAQ:OPK
Opko Health — Shareholder Meeting (June 2008)
19 slides from Opko Health's shareholder meeting presentation, Jun 11, 2008
Slide 1: Stockholders Meeting
STOCKHOLDERS MEETING JUNE 11, 2008 MIAMI, FL
Slide 2: Cautionary Statement
Cautionary Statement This presentation contains "forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “sho
Slide 3: OPKO specialty healthcare company overview
Slide 4: Financial History
OPKO Financial History * Capital Investment — Acuity Pharmaceuticals & Froptix (Pre-acquisition) $20 Million — eXegenics (Public Company) $16Million — The Frost Group (December, 2007) $20 Million Total Capital Investment $56 Million ¢ — Line of Credit — The Frost Group (Fully funded) $12 Million Tot
Slide 5: Target Ophthalmic Markets
Suet: Declon Reouces Vongan, MS NEL Anat prs nd Ay Ents Target Ophthalmic Markets
Slide 6: Pipeline
OPKO Pipeline Products Mode of Expected Action Approval Bevasiranib Gene Silencing ‘Wet AMD ‘ANt-VEGF-A 2012 US Civamide Vanillois Dry Eye 2011 Ex-US Receptor 2012 US Inhibitor Collagen Ocular Surface Prevention of 2009 US Aquashunt Drainage ——_—Refractory Glaucoma 2010 ExUS ‘Shunt 2012 US Bevasiran
Slide 7: Drug Bevasiranib
OPKO Drug Bevasiranib Indication Wet-AMD Opportunity Continued unmet need despite anti- VEGF Treatment; significant treatment burden due to monthly injections Anti-VEGF-A Gene Silencing Platform
Slide 8: Bevasiranib
OPKO Bevasiranib Development Strategy Project Status Clinical Present Pivotal Study » Reduce Treatment Burden ® 50% Enrollmentin this ® Maintain Visual Acuity Gains complete produced by anti-VEGFA © Expect full enrollment in agents this study by 04, 2008 ® Speed to Market * Global Clinical Studies &
Slide 9: Device AquaShunt
OPKO Device AquaShunt Indication Refractory Glaucoma Opportunity Continued unmet need due to failed <—_ surgeries and ineffective shunts A Novel Drainage Device
Slide 10: Current Treatment Options & Limitations
OPKO Current Treatment Options & Limitations Medications 2.3 million patients (U.S.) * Poor compliance - Unpleasant / dangerous side effects * High costs + Lack of efficacy Laser 300,000 procedures/year * 10% failure rate per year « Uncertain results with repeats ° Much less effective than surgery S
Slide 11: AquaShunt
OPKO AquaShunt Development Strategy Clinical * Maintain lOP with or with out drugs in > 75% of patients for > 5 years Regulatory & Commercial » Speed to Market * Global Development © EU, Latin America & ROW Focus Project Status Clinical ® First human studies expected to begin Q4, 2008 » Pivotal US s
Slide 12: Device Biocompatible Wound Dressing
OPKO Device Biocompatible Wound Dressing Indication Prevention of endophthalmitis Opportunity Increased use of sutureless surgeries and intravitreal injections has increased risk of endophthalmitis Surgical Wound Dressing 11
Slide 13: Biocompatible Wound Dressing
OPKO Biocompatible Wound Dressing Development Strategy Project Status Clinical Wound Dressing 510K STUDY * Provide a biocompatible wound dressing to prevent « Biocompatible Surgical endophthalmitis after small- Wound Dressing gauge surgery or intravitreal * Human study expected injections ; tostart
Slide 14: Drug Civamide
OPKO Drug Civamide Indication Dry Eye Opportunity Current treatments are ineffective Novel Route of Administration 13
Slide 15: Development Strategy
OPKO Development Strategy Civamide Project Status * Increase tear production in patients with moderate to severe dry eye Regulatory & Comm * Speed to Market © Global Development © EU, Latin America & RoW Focus ® First human study expected to start in Q4, 2008 ® Study sites in US 14
Slide 16: Instrumentation
OPKO Instrumentation ¢ Development, manufacture, marketing and sale of diagnostic ophthalmic systems. ¢ Ultrasound * Optical Coherence Tomography as
Slide 17: Instrumentation
OPKO Instrumentation * Ophthalmic Ultrasound is estimated to be a $70m product category in the ophthalmic market © Types of Ultrasound: — A-Scan * Determine eye length for calculation of intraocular lens power. — B-Scan ¢ 2-Dimensional imaging of the posterior segment of the eye. - 3DBScan ¢ 3-Dimen
Slide 18: Instrumentation
OPKO Instrumentation * Optical Coherence Tomography (OCT) is estimated to be $200 million market growing 35% annually. ¢ Spectral OCT SLO™ combines Optical Coherence Tomography with a Confocal Scanning Laser Ophthalmoloscope (SLO) for retina and Glaucoma. ¢ OPKO’s Spectral OCT SLO is the only unit o
Slide 19: Stockholders Meeting
STOCKHOLDERS MEETING JUNE 11, 2008 MIAMI, FL 18